• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于形状和基于药效团的计算筛选在鉴定 II 型蛋白激酶抑制剂中的应用。

Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.

机构信息

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, UK.

出版信息

J Comput Aided Mol Des. 2011 Jun;25(6):569-81. doi: 10.1007/s10822-011-9442-0. Epub 2011 Jun 17.

DOI:10.1007/s10822-011-9442-0
PMID:21681554
Abstract

The identification of new, potent and selective inhibitors of important protein kinase targets is a major goal of drug discovery. Here we analyze the crystal structures of 55 protein kinase complexes with Type II inhibitors and find they adopt a conserved twisted V-shape, with an angle of 121 ± 8° and twist of 78 ± 8°. The tightly conserved twist appears important in ensuring ligands curve around the protein backbone and towards the deep pocket. From this, we develop predictive pharmacophore- and shape-based screens to identify Type II inhibitors from a database which also contains Type I inhibitors as decoys. Both approaches exhibit a good level of discrimination for Type II molecules. The most effective pharmacophore model requires six features and three excluded volume regions. Shape-based screening using ROCS generally performs at least as well as pharmacophore approaches. There is only a moderate dependence of shape-based or pharmacophore-based screens on the underlying conformer generator (MOE, Macromodel, Omega and SPE), as well as on ligand linkage chemistry (amide and urea). Finally, we apply our approach to retrieval of Type II inhibitors from a modified version of the DUD database, containing over 104,000 compounds. We observe good enrichment, providing further evidence that the in silico screens developed here will constitute useful guides for identification of small molecule inhibitors targetting protein kinases in their inactive conformational state.

摘要

鉴定新型、高效且选择性的蛋白激酶靶标抑制剂是药物研发的主要目标。在此,我们分析了 55 种与 II 型抑制剂结合的蛋白激酶复合物的晶体结构,发现它们都采用保守的扭曲 V 型构象,夹角为 121±8°,扭转度为 78±8°。这种紧密保守的扭转对确保配体围绕蛋白骨架弯曲并进入深口袋非常重要。基于此,我们开发了基于药效团和形状的虚拟筛选方法,从包含 I 型抑制剂作为诱饵的数据库中识别 II 型抑制剂。这两种方法都能很好地区分 II 型分子。最有效的药效团模型需要六个特征和三个排除体积区域。使用 ROCS 的基于形状的筛选通常与药效团方法一样有效。基于形状或药效团的筛选对基础构象生成器(MOE、Macromodel、Omega 和 SPE)以及配体连接化学(酰胺和脲)的依赖性适中。最后,我们将我们的方法应用于从包含超过 104,000 种化合物的 DUD 数据库的修改版本中检索 II 型抑制剂。我们观察到良好的富集,进一步证明了这里开发的计算机筛选将成为鉴定处于非活性构象状态的蛋白激酶小分子抑制剂的有用指南。

相似文献

1
Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.基于形状和基于药效团的计算筛选在鉴定 II 型蛋白激酶抑制剂中的应用。
J Comput Aided Mol Des. 2011 Jun;25(6):569-81. doi: 10.1007/s10822-011-9442-0. Epub 2011 Jun 17.
2
Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.基于结构和形状互补的药效团模型在新型细胞周期检查点激酶 1 抑制剂发现中的应用。
J Mol Model. 2010 Jul;16(7):1195-204. doi: 10.1007/s00894-009-0630-y. Epub 2009 Dec 18.
3
DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.DFG模型:预测处于非活性状态的蛋白激酶结构以用于基于结构的II型抑制剂发现。
ACS Chem Biol. 2015 Jan 16;10(1):269-78. doi: 10.1021/cb500696t. Epub 2014 Dec 9.
4
A pharmacophore map of small molecule protein kinase inhibitors.小分子蛋白激酶抑制剂的药效团图谱。
J Chem Inf Model. 2007 Nov-Dec;47(6):2374-82. doi: 10.1021/ci700244t. Epub 2007 Oct 17.
5
Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.使用活性结构预测蛋白激酶的非活性构象:Ⅱ型抑制剂的构象选择。
PLoS One. 2011;6(7):e22644. doi: 10.1371/journal.pone.0022644. Epub 2011 Jul 27.
6
Fragment-based approaches to the discovery of kinase inhibitors.基于片段的激酶抑制剂发现方法。
Methods Enzymol. 2014;548:69-92. doi: 10.1016/B978-0-12-397918-6.00003-3.
7
Identification of type-II inhibitors using kinase structures.利用激酶结构鉴定 II 型抑制剂。
Chem Biol Drug Des. 2012 Nov;80(5):657-64. doi: 10.1111/j.1747-0285.2012.01443.x. Epub 2012 Sep 3.
8
Multi-Pharmacophore Modeling of Caspase-3 Inhibitors using Crystal, Dock and Flexible Conformation Schemes.使用晶体、对接和柔性构象方案对Caspase-3抑制剂进行多药效团建模
Comb Chem High Throughput Screen. 2018;21(1):26-40. doi: 10.2174/1386207321666180102114917.
9
Affinity reagents that target a specific inactive form of protein kinases.靶向蛋白激酶特定无活性形式的亲和试剂。
Chem Biol. 2010 Feb 26;17(2):195-206. doi: 10.1016/j.chembiol.2010.01.008.
10
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.基于药效团模型的虚拟筛选寻找新型布鲁顿酪氨酸激酶抑制剂
J Mol Model. 2019 Jun 6;25(7):179. doi: 10.1007/s00894-019-4047-y.

引用本文的文献

1
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.PKIDB:一个经过精心策划、注释和更新的临床试验中蛋白激酶抑制剂数据库。
Molecules. 2018 Apr 15;23(4):908. doi: 10.3390/molecules23040908.
2
Conformational landscape and low lying excited states of imatinib.伊马替尼的构象态势和低激发态
J Mol Model. 2015 Apr;21(4):84. doi: 10.1007/s00894-015-2639-8. Epub 2015 Mar 13.

本文引用的文献

1
Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition.小分子蛋白激酶抑制剂。第二部分:II 型和 III 型抑制的新型药效团方法。
Expert Opin Drug Discov. 2008 Dec;3(12):1427-49. doi: 10.1517/17460440802580106.
2
Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition.小分子蛋白激酶抑制剂。第一部分:I 型抑制的传统药效团方法的例外。
Expert Opin Drug Discov. 2008 Dec;3(12):1409-25. doi: 10.1517/17460440802579975.
3
Optimal assignment methods for ligand-based virtual screening.
基于配体的虚拟筛选的最优分配方法。
J Cheminform. 2009 Aug 25;1:14. doi: 10.1186/1758-2946-1-14.
4
Through the "gatekeeper door": exploiting the active kinase conformation.通过“守门人之门”:利用活性激酶构象
J Med Chem. 2010 Apr 8;53(7):2681-94. doi: 10.1021/jm901443h.
5
Conformational sampling with stochastic proximity embedding and self-organizing superimposition: establishing reasonable parameters for their practical use.采用随机临近嵌入和自组织叠加进行构象采样:为实际应用确定合理的参数。
J Chem Inf Model. 2009 Dec;49(12):2786-800. doi: 10.1021/ci9001926.
6
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.AP24534是一种用于治疗慢性髓性白血病的泛BCR-ABL抑制剂,能有效抑制T315I突变体并克服基于突变的耐药性。
Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
7
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.非铰链结合的吡唑并[1,5-a]嘧啶作为强效 B-Raf 激酶抑制剂。
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6519-23. doi: 10.1016/j.bmcl.2009.10.049. Epub 2009 Oct 26.
8
Conformational analysis of macrocycles: finding what common search methods miss.大环化合物的构象分析:发现常见搜索方法所遗漏的内容。
J Chem Inf Model. 2009 Oct;49(10):2242-59. doi: 10.1021/ci900238a.
9
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.开发一种荧光标记激酶测定系统,用于检测和表征别构激酶抑制剂。
J Am Chem Soc. 2009 Sep 23;131(37):13286-96. doi: 10.1021/ja902010p.
10
Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology.基于片段的先导化合物生成:通过高效的片段筛选技术鉴定种子片段。
J Comput Aided Mol Des. 2009 Aug;23(8):501-11. doi: 10.1007/s10822-009-9288-x. Epub 2009 Jun 17.